{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:54:57Z","timestamp":1788328497640,"version":"build-2803163510"},"reference-count":124,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,3]],"date-time":"2023-01-03T00:00:00Z","timestamp":1672704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>This review presents current updates of pancreatic enzyme replacement therapy in children with cystic fibrosis based on literature published in the last decade and some special considerations regarding pancreatic enzyme replacement therapy in the era of new therapies, such as cystic fibrosis transmembrane conductance regulator modulator therapies. Few articles evaluate the efficacy of pancreatic enzyme replacement therapy in the pediatric population, and most studies also included children and adults with cystic fibrosis. Approximately 85% of cystic fibrosis patients have exocrine pancreatic insufficiency and need pancreatic enzyme replacement therapy. Fecal elastase is the most commonly used diagnostic test for exocrine pancreatic insufficiency, although this value can fluctuate over time. While it is used as a diagnostic test, it cannot be used for monitoring the effectiveness of pancreatic enzyme replacement therapy and for adjusting doses. Pancreatic enzyme replacement therapy, the actual treatment for exocrine pancreatic insufficiency, is essential in children with cystic fibrosis to prevent malabsorption and malnutrition and needs to be urgently initiated. This therapy presents many considerations for physicians, patients, and their families, including types and timing of administration, dose monitoring, and therapy failures. Based on clinical trials, pancreatic enzyme replacement therapy is considered effective and well-tolerated in children with cystic fibrosis. An important key point in cystic fibrosis treatment is the recent hypothesis that cystic fibrosis transmembrane conductance regulator modulators could improve pancreatic function, further studies being essential. Pancreatic enzyme replacement therapy is addressed a complication of the disease (exocrine pancreatic insufficiency), while modulators target the defective cystic fibrosis transmembrane conductance regulator protein. Exocrine pancreatic insufficiency in cystic fibrosis remains an active area of research in this era of cystic fibrosis transmembrane conductance regulator modulator therapies. This new therapy could represent an example of personalized medicine in cystic fibrosis patients, with each class of modulators being addressed to patients with specific genetic mutations.<\/jats:p>","DOI":"10.3390\/pharmaceutics15010162","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T01:42:44Z","timestamp":1672796564000},"page":"162","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Current and Future Therapeutic Approaches of Exocrine Pancreatic Insufficiency in Children with Cystic Fibrosis in the Era of Personalized Medicine"],"prefix":"10.3390","volume":"15","author":[{"given":"Mirela-Elena","family":"Ritivoiu","sequence":"first","affiliation":[{"name":"Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Alessandrescu-Rusescu National Institute for Mother and Child Health, 020395 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6568-6846","authenticated-orcid":false,"given":"Cristina Manuela","family":"Dr\u0103goi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020956 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dumitru","family":"Matei","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Alessandrescu-Rusescu National Institute for Mother and Child Health, 020395 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iustina Violeta","family":"Stan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Alessandrescu-Rusescu National Institute for Mother and Child Health, 020395 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina Crengu\u0163a","family":"Nicolae","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020956 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6194-6797","authenticated-orcid":false,"given":"Mihai","family":"Craiu","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Alessandrescu-Rusescu National Institute for Mother and Child Health, 020395 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5693-8012","authenticated-orcid":false,"given":"Ion-Bogdan","family":"Dumitrescu","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 020956 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina Angelica","family":"Ciolpan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cCarol Davila\u201d University of Medicine and Pharmacy, 050474 Bucharest, Romania"},{"name":"Alessandrescu-Rusescu National Institute for Mother and Child Health, 020395 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,3]]},"reference":[{"key":"ref_1","unstructured":"Orenti, A., Zolin, A., Jung, A., and van Rens, J. (2022, November 13). ECFSPR Annual Report 2020. Available online: https:\/\/www.ecfs.eu\/projects\/ecfs-patient-registry\/annual-reports."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.5152\/balkanmedj.2021.21199","article-title":"The Genetic Analysis of Cystic Fibrosis Patients with Seven Novel Mutations in the CFTR Gene in the Central Anatolian Region of Turkey","volume":"38","author":"Erdogan","year":"2021","journal-title":"Balk. Med. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s43042-021-00164-x","article-title":"Molecular Analysis of CFTR Gene Mutations among Iraqi Cystic Fibrosis Patients","volume":"22","author":"Thejeal","year":"2021","journal-title":"Egypt. J. Med. Hum. Genet."},{"key":"ref_4","unstructured":"(2022, October 10). CFTR2. Available online: https:\/\/cftr2.org\/."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"BSR20212006","DOI":"10.1042\/BSR20212006","article-title":"Molecular Mechanisms of Cystic Fibrosis\u2014How Mutations Lead to Misfunction and Guide Therapy","volume":"42","author":"Farinha","year":"2022","journal-title":"Biosci. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fphar.2019.00121","article-title":"Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine","volume":"10","author":"Pranke","year":"2019","journal-title":"Front. Pharm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S2213-2600(12)70057-7","article-title":"A New Era in the Treatment of Cystic Fibrosis: Correction of the Underlying CFTR Defect","volume":"1","author":"Boyle","year":"2013","journal-title":"Lancet Respir. Med."},{"key":"ref_8","first-page":"91","article-title":"Precision Medicine Based on CFTR Genotype for People with Cystic Fibrosis","volume":"15","author":"Haq","year":"2022","journal-title":"Pharmgenom. Pers. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/d41586-019-00781-y","article-title":"Pore-Forming Small Molecules Offer a Promising Way to Tackle Cystic Fibrosis","volume":"567","author":"Sheppard","year":"2019","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1378\/chest.10-2077","article-title":"Cystic Fibrosis Transmembrane Conductance Regulator Intracellular Processing, Trafficking, and Opportunities for Mutation-Specific Treatment","volume":"139","author":"Rogan","year":"2011","journal-title":"Chest"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.chest.2018.04.036","article-title":"Ion Channel Modulators in Cystic Fibrosis","volume":"154","author":"Gentzsch","year":"2018","journal-title":"Chest"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jcf.2017.08.008","article-title":"CFTR Structure","volume":"17","author":"Callebaut","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00018-016-2391-y","article-title":"Role of CFTR in Epithelial Physiology","volume":"74","author":"Gray","year":"2017","journal-title":"Cell Mol. Life Sci."},{"key":"ref_14","unstructured":"Atlas, A., and Rosh, J. (2005). Pediatric Gastroenterology and Liver Disease, Elsevier."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1801297","DOI":"10.1183\/13993003.01297-2018","article-title":"Pathological Mucus and Impaired Mucus Clearance in Cystic Fibrosis Patients Results from Increased Concentration, Not Altered PH","volume":"52","author":"Hill","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.3389\/fphys.2018.01585","article-title":"Cystic Fibrosis of the Pancreas: The Role of CFTR Channel in the Regulation of Intracellular Ca2+ Signaling and Mitochondrial Function in the Exocrine Pancreas","volume":"9","author":"Pallagi","year":"2018","journal-title":"Front. Physiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(16)30032-7","article-title":"Partial Restoration of Pancreatic Function in a Child with Cystic Fibrosis","volume":"4","author":"Howlett","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.jcf.2017.06.011","article-title":"Pancreatic Insufficiency in Cystic Fibrosis","volume":"16","author":"Singh","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Rachel, M., Topolewicz, S., \u015aliwczy\u0144ski, A., and Galiniak, S. (2020). Managing Cystic Fibrosis in Polish Healthcare. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17207630"},{"key":"ref_20","first-page":"1383","article-title":"Maldigestion Associated with Exocrine Pancreatic Insufficiency: Implications of Gastrointestinal Physiology and Properties of Enzyme Preparations for a Cause-Related and Patient-Tailored Treatment","volume":"90","author":"Bruno","year":"1995","journal-title":"Am. J. Gastroenterol."},{"key":"ref_21","first-page":"55","article-title":"Enzyme Replacement Therapy for Pancreatic Insufficiency: Present and Future","volume":"4","author":"Fieker","year":"2011","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1136\/gut.52.8.1159","article-title":"Molecular Consequences of Cystic Fibrosis Transmembrane Regulator (CFTR) Gene Mutations in the Exocrine Pancreas","volume":"52","author":"Ahmed","year":"2003","journal-title":"Gut"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1046\/j.1365-2362.2001.00876.x","article-title":"Analysis of Exocrine Pancreatic Function in Cystic Fibrosis: One Mild CFTR Mutation Does Not Exclude Pancreatic Insufficiency","volume":"31","author":"Walkowiak","year":"2001","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1046\/j.1365-2036.2003.01495.x","article-title":"Review Article: Pancreatic Function Testing","volume":"17","author":"Chowdhury","year":"2003","journal-title":"Aliment. Pharm. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/0016-5085(85)90029-0","article-title":"Diagnosis of Chronic Pancreatitis","volume":"88","author":"Niederau","year":"1985","journal-title":"Gastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00006676-199804000-00022","article-title":"Chronic Pancreatitis: Functional Testing","volume":"16","author":"Ochi","year":"1998","journal-title":"Pancreas"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Freswick, P.N., Reid, E.K., and Mascarenhas, M.R. (2022). Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis. Nutrients, 14.","DOI":"10.3390\/nu14071341"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1542\/peds.110.1.e7","article-title":"Fecal Elastase-1 Is Superior to Fecal Chymotrypsin in the Assessment of Pancreatic Involvement in Cystic Fibrosis","volume":"110","author":"Walkowiak","year":"2002","journal-title":"Pediatrics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1651-2227.2004.tb02715.x","article-title":"Faecal Elastase-1 Test Is Superior to Faecal Lipase Test in the Assessment of Exocrine Pancreatic Function in Cystic Fibrosis","volume":"93","author":"Walkowiak","year":"2004","journal-title":"Acta Paediatr."},{"key":"ref_30","unstructured":"(2022, October 10). NHS. Available online: https:\/\/www.rbht.nhs.uk\/childrencf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.clnu.2016.03.004","article-title":"ESPEN-ESPGHAN-ECFS Guidelines on Nutrition Care for Infants, Children, and Adults with Cystic Fibrosis","volume":"35","author":"Turck","year":"2016","journal-title":"Clin. Nutr."},{"key":"ref_32","first-page":"106","article-title":"Gastroesophageal Reflux Disease and Need for Antireflux Surgery in Children with Cystic Fibrosis: A Systematic Review on Inciden.nce, Surgical Complications, and Postoperative Outcomes","volume":"31","author":"Ng","year":"2020","journal-title":"Eur. J. Pediatr. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jcf.2021.08.021","article-title":"Diagnosing Constipation in Patients with Cystic Fibrosis Applying ESPGHAN Criteria","volume":"21","author":"Stefano","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Patel, D., Shan, A., Mathews, S., and Sathe, M. (2022). Understanding Cystic Fibrosis Comorbidities and Their Impact on Nutritional Management. Nutrients, 14.","DOI":"10.3390\/nu14051028"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.paed.2020.07.002","article-title":"Gastrointestinal Complications of Cystic Fibrosis","volume":"30","author":"Ng","year":"2020","journal-title":"Paediatr. Child. Health"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.4254\/wjh.v13.i11.1727","article-title":"Cystic Fibrosis Associated Liver Disease in Children","volume":"13","author":"Valamparampil","year":"2021","journal-title":"World J. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/MPG.0000000000002443","article-title":"Nutrition Support of Children With Chronic Liver Diseases: A Joint Position Paper of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition","volume":"69","author":"Mouzaki","year":"2019","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/ped.14417","article-title":"The Effects of Nutritional Status and Intervention on Pulmonary Functions in Pediatric Cystic Fibrosis Patients","volume":"63","author":"Kilinc","year":"2021","journal-title":"Pediatr. Int."},{"key":"ref_39","first-page":"100272","article-title":"Body Composition in Individuals with Cystic Fibrosis","volume":"26","author":"Soltman","year":"2021","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e220740","DOI":"10.1001\/jamanetworkopen.2022.0740","article-title":"Association of Body Mass Index With Clinical Outcomes in Patients With Cystic Fibrosis: A Systematic Review and Meta-Analysis","volume":"5","author":"Nagy","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Nicolson, W.B., Bailey, J., Alotaibi, N.Z., Krick, S., and Lowman, J.D. (2022). Effects of Exercise on Nutritional Status in People with Cystic Fibrosis: A Systematic Review. Nutrients, 14.","DOI":"10.3390\/nu14050933"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/ncp.10251","article-title":"Association Between Fat-Free Mass and Pulmonary Function in Patients With Cystic Fibrosis: A Narrative Review","volume":"34","author":"Gomes","year":"2019","journal-title":"Nutr. Clin. Pr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jand.2020.03.014","article-title":"Effect of CFTR Modulators on Anthropometric Parameters in Individuals with Cystic Fibrosis: An Evidence Analysis Center Systematic Review","volume":"121","author":"Bailey","year":"2021","journal-title":"J. Acad. Nutr. Diet."},{"key":"ref_44","first-page":"100276","article-title":"Obesity in Cystic Fibrosis","volume":"26","author":"Kutney","year":"2021","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_45","first-page":"S81","article-title":"Factors Associated with Weight Gain and Improvement in FEV1 in People with Cystic Fibrosis on Elexacaftor-Tezacaftor-Ivacaftor","volume":"Volume 55","author":"Khare","year":"2020","journal-title":"Pediatric Pulmonology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1513\/AnnalsATS.202101-057OC","article-title":"Impact of Cystic Fibrosis Transmembrane Conductance Regulator Therapy on Chronic Rhinosinusitis and Health Status: Deep Learning CT Analysis and Patient-Reported Outcomes","volume":"19","author":"Beswick","year":"2022","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.clnu.2019.12.029","article-title":"Overweight, Obesity and Significant Weight Gain in Adult Patients with Cystic Fibrosis Association with Lung Function and Cardiometabolic Risk Factors","volume":"39","author":"Bonhoure","year":"2020","journal-title":"Clin. Nutr."},{"key":"ref_48","unstructured":"(2022, November 13). 2021 Annual Data Report. Available online: https:\/\/www.cff.org."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1097\/PCC.0000000000002358","article-title":"Outcomes of Children With Cystic Fibrosis Admitted to PICUs","volume":"21","author":"Smith","year":"2020","journal-title":"Pediatr Crit Care Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.jcf.2019.08.011","article-title":"Cystic Fibrosis Related Diabetes: Nutrition and Growth Considerations","volume":"18","author":"Kaminski","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1440-1754.1999.00363.x","article-title":"Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis: Australian Guidelines. Pediatric Gastroenterological Society and the Dietitians Association of Australia","volume":"35","author":"Anthony","year":"1999","journal-title":"J. Paediatr. Child Health"},{"key":"ref_52","first-page":"246","article-title":"Consensus Report on Nutrition for Pediatric Patients with Cystic Fibrosis","volume":"35","author":"Borowitz","year":"2002","journal-title":"J Pediatr Gastroenterol. Nutr."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1569-1993(02)00032-2","article-title":"Nutrition in Patients with Cystic Fibrosis: A European Consensus","volume":"1","author":"Sinaasappel","year":"2002","journal-title":"J. Cyst. Fibros."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Olsen, M.F., Kj\u00f8ller-Svarre, M.S., M\u00f8ller, G., Katzenstein, T.L., Nielsen, B.U., Pressler, T., Lewis, J.I., Mathiesen, I.H., M\u00f8lgaard, C., and Faurholt-Jepsen, D. (2022). Correlates of Pancreatic Enzyme Replacement Therapy Intake in Adults with Cystic Fibrosis: Results of a Cross-Sectional Study. Nutrients, 14.","DOI":"10.3390\/nu14071330"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1080\/17474124.2018.1438188","article-title":"Functional Abdominal Pain Disorders in Children","volume":"12","author":"Rajindrajith","year":"2018","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.jcf.2020.11.016","article-title":"Clinical Evaluation of an Evidence-Based Method Based on Food Characteristics to Adjust Pancreatic Enzyme Supplements Dose in Cystic Fibrosis","volume":"20","author":"Boon","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/j.1552-4604.1994.tb03981.x","article-title":"Clinical Pharmacology of Pancreatic Enzymes in Patients with Cystic Fibrosis and in Vitro Performance of Microencapsulated Formulations","volume":"34","author":"Kraisinger","year":"1994","journal-title":"J. Clin. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0022-3476(95)70153-2","article-title":"Use of Pancreatic Enzyme Supplements for Patients with Cystic Fibrosis in the Context of Fibrosing Colonopathy","volume":"127","author":"Borowitz","year":"1995","journal-title":"J. Pediatr."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Cystic Fibrosis Foundation, Borowitz, D., Robinson, K.A., Rosenfeld, M., Davis, S.D., Sabadosa, K.A., Spear, S.L., Michel, S.H., Parad, R.B., and White, T.B. (2009). Cystic Fibrosis Foundation Evidence-Based Guidelines for Management of Infants with Cystic Fibrosis. J. Pediatr., 155, S73\u2013S93.","DOI":"10.1016\/j.jpeds.2009.09.001"},{"key":"ref_60","unstructured":"(2022, December 17). Drugs@FDA: FDA-Approved Drugs, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jpeds.2004.09.003","article-title":"Pancreatic Enzyme Therapy and Clinical Outcomes in Patients with Cystic Fibrosis","volume":"146","author":"Baker","year":"2005","journal-title":"J. Pediatr."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2147\/TCRM.S3123","article-title":"Delayed Release Pancrelipase for the Treatment of Pancreatic Exocrine Insufficiency Associated with Cystic Fibrosis","volume":"4","author":"Baker","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1002\/ppul.25431","article-title":"Use of Proton Pump Inhibitors Is Associated with Lower Hemoglobin Levels in People with Cystic Fibrosis","volume":"56","author":"Gifford","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00004836-200104000-00008","article-title":"The Exacerbation of Pancreatic Endocrine Dysfunction by Potent Pancreatic Exocrine Supplements in Patients with Chronic Pancreatitis","volume":"32","author":"Cariem","year":"2001","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/01.mpa.0000226884.32957.5e","article-title":"The Effects of Oral Pancreatic Enzymes (Creon 10 Capsule) on Steatorrhea: A Multicenter, Placebo-Controlled, Parallel Group Trial in Subjects with Chronic Pancreatitis","volume":"33","author":"Safdi","year":"2006","journal-title":"Pancreas"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1111\/j.1572-0241.2000.02244.x","article-title":"A Comparison of the Efficacy and Tolerance of Pancrelipase and Placebo in the Treatment of Steatorrhea in Cystic Fibrosis Patients with Clinical Exocrine Pancreatic Insufficiency","volume":"95","author":"Stern","year":"2000","journal-title":"Am. J. Gastroenterol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1056\/NEJM199705013361803","article-title":"High-Dose Pancreatic-Enzyme Supplements and Fibrosing Colonopathy in Children with Cystic Fibrosis","volume":"336","author":"FitzSimmons","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_68","unstructured":"U.S. Food and Drug Administration (2022, October 10). Questions and Answers: Delayed-Release Pancreatic Enzyme Product Receives FDA Approval, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/postmarket-drug-safety-information-patients-and-providers."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jcf.2009.08.008","article-title":"Efficacy and Safety of Creon 24,000 in Subjects with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis","volume":"8","author":"Trapnell","year":"2009","journal-title":"J. Cyst. Fibros."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jcf.2009.07.006","article-title":"EUR-1008 Pancreatic Enzyme Replacement Is Safe and Effective in Patients with Cystic Fibrosis and Pancreatic Insufficiency","volume":"8","author":"Wooldridge","year":"2009","journal-title":"J. Cyst. Fibros."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clinthera.2010.01.012","article-title":"Efficacy and Tolerability of a New Formulation of Pancrelipase Delayed-Release Capsules in Children Aged 7 to 11 Years with Exocrine Pancreatic Insufficiency and Cystic Fibrosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover, Superiority Study","volume":"32","author":"Graff","year":"2010","journal-title":"Clin. Ther."},{"key":"ref_72","first-page":"CD013488","article-title":"Dosing Regimens for Pancreatic Enzyme Replacement Therapy (PERT) in Cystic Fibrosis","volume":"2019","author":"Ng","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1479973119900612","DOI":"10.1177\/1479973119900612","article-title":"Hospitalization Rates among Patients with Cystic Fibrosis Using Pancreatic Enzyme Replacement Therapy","volume":"17","author":"Trapnell","year":"2020","journal-title":"Chronic Respir. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/ncp.10593","article-title":"Utility of Mid-Upper Arm Circumference in Diagnosing Malnutrition in Children With Cystic Fibrosis","volume":"35","author":"Phong","year":"2020","journal-title":"Nutr. Clin. Pr."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS Best Practice Guidelines: The 2018 Revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Kapnadak, S.G., Ramos, K.J., Lopriore, A.M., Goss, C.H., and Aitken, M.L. (2019). A Survey Identifying Nutritional Needs in a Contemporary Adult Cystic Fibrosis Cohort. BMC Nutr., 5.","DOI":"10.1186\/s40795-018-0266-3"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Poulimeneas, D., Grammatikopoulou, M.G., Petrocheilou, A., Kaditis, A.G., and Vassilakou, T. (2020). Triage for Malnutrition Risk among Pediatric and Adolescent Outpatients with Cystic Fibrosis, Using a Disease-Specific Tool. Children, 7.","DOI":"10.3390\/children7120269"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.jand.2020.03.015","article-title":"Academy of Nutrition and Dietetics: 2020 Cystic Fibrosis Evidence Analysis Center Evidence-Based Nutrition Practice Guideline","volume":"121","author":"McDonald","year":"2021","journal-title":"J. Acad. Nutr. Diet."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00408-019-00218-3","article-title":"Nutritional Status in Childhood as a Prognostic Factor in Patients with Cystic Fibrosis","volume":"197","author":"Ashkenazi","year":"2019","journal-title":"Lung"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"20406223221108628","DOI":"10.1177\/20406223221108627","article-title":"Personalized Medicine with Drugs Targeting the Underlying Protein Defect in Cystic Fibrosis: Is Monitoring of Treatment Response Necessary?","volume":"13","author":"Niedermayr","year":"2022","journal-title":"Ther. Adv. Chronic Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/014107689809134S07","article-title":"Pathology of Pancreatic and Intestinal Disorders in Cystic Fibrosis","volume":"91","author":"Wilschanski","year":"1998","journal-title":"J. R. Soc. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jada.2008.02.020","article-title":"Clinical Practice Guidelines on Growth and Nutrition Subcommittee; Ad Hoc Working Group Evidence-Based Practice Recommendations for Nutrition-Related Management of Children and Adults with Cystic Fibrosis and Pancreatic Insufficiency: Results of a Systematic Review","volume":"108","author":"Stallings","year":"2008","journal-title":"J. Am. Diet. Assoc."},{"key":"ref_83","first-page":"9","article-title":"Changing Paradigms in the Treatment of Gastrointestinal Complications of Cystic Fibrosis in the Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulators","volume":"42","author":"Konrad","year":"2022","journal-title":"Paediatr. Respir. Rev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"248","DOI":"10.37897\/RJMP.2021.2.23","article-title":"Acute Pancreatitis Prevalence in Children with Cystic Fibrosis and PIP Score Prediction Applicability","volume":"16","author":"Comanici","year":"2021","journal-title":"Rom. J. Med. Pract."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"12757","DOI":"10.1073\/pnas.1815287115","article-title":"Molecular Structure of the ATP-Bound, Phosphorylated Human CFTR","volume":"115","author":"Zhang","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic Fibrosis","volume":"373","author":"Freedman","year":"2009","journal-title":"Lancet"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"914790","DOI":"10.3389\/fped.2022.914790","article-title":"The Exocrine Pancreas in Cystic Fibrosis in the Era of CFTR Modulation: A Mini Review","volume":"10","author":"McKay","year":"2022","journal-title":"Front. Pediatr."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/apm.12915","article-title":"Cystic Fibrosis\u2014An Example of Personalized and Precision Medicine","volume":"127","author":"Skov","year":"2019","journal-title":"APMIS"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine","volume":"10","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_90","first-page":"275","article-title":"CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis","volume":"7","year":"2016","journal-title":"Front. Pharm."},{"key":"ref_91","unstructured":"(2022, November 22). CFF. Available online: https:\/\/www.cff.org\/."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pharmthera.2014.06.005","article-title":"New Pharmacological Approaches for Cystic Fibrosis: Promises, Progress, Pitfalls","volume":"145","author":"Bell","year":"2015","journal-title":"Pharm. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/MCP.0000000000000629","article-title":"Prevention of Malnutrition in Cystic Fibrosis","volume":"25","author":"Slae","year":"2019","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2019.09.013","article-title":"VX12-770-113 Study Team Ivacaftor in Cystic Fibrosis with Residual Function: Lung Function Results from an N-of-1 Study","volume":"19","author":"Nick","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1164\/rccm.202008-3177OC","article-title":"Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial","volume":"203","author":"Davies","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Gramegna, A., Contarini, M., Aliberti, S., Casciaro, R., Blasi, F., and Castellani, C. (2020). From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165882"},{"key":"ref_97","unstructured":"(2022, November 13). CFTR Modulator Therapies|Cystic Fibrosis Foundation. Available online: https:\/\/www.cff.org\/managing-cf\/cftr-modulator-therapies."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jcf.2019.05.015","article-title":"Disease Progression in Patients with Cystic Fibrosis Treated with Ivacaftor: Data from National US and UK Registries","volume":"19","author":"Volkova","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jcf.2017.07.001","article-title":"Retrospective Observational Study of French Patients with Cystic Fibrosis and a Gly551Asp-CFTR Mutation after 1 and 2 years of Treatment with Ivacaftor in a Real-World Setting","volume":"17","author":"Hubert","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","article-title":"Efficacy and Safety of Lumacaftor and Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis Homozygous for F508del-CFTR: A Randomised, Placebo-Controlled Phase 3 Trial","volume":"5","author":"Ratjen","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S2213-2600(21)00069-2","article-title":"Long-Term Safety of Lumacaftor-Ivacaftor in Children Aged 2\u20135 Years with Cystic Fibrosis Homozygous for the F508del-CFTR Mutation: A Multicentre, Phase 3, Open-Label, Extension Study","volume":"9","author":"Hoppe","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"139983","DOI":"10.1172\/jci.insight.139983","article-title":"Allosteric Folding Correction of F508del and Rare CFTR Mutants by Elexacaftor-Tezacaftor-Ivacaftor (Trikafta) Combination","volume":"5","author":"Veit","year":"2020","journal-title":"JCI Insight"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Sondo, E., Cresta, F., Pastorino, C., Tomati, V., Capurro, V., Pesce, E., Lena, M., Iacomino, M., Baffico, A.M., and Coviello, D. (2022). The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor\/Tezacaftor\/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063175"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and Safety of the Elexacaftor plus Tezacaftor plus Ivacaftor Combination Regimen in People with Cystic Fibrosis Homozygous for the F508del Mutation: A Double-Blind, Randomised, Phase 3 Trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Bass, R., Brownell, J.N., and Stallings, V.A. (2021). The Impact of Highly Effective CFTR Modulators on Growth and Nutrition Status. Nutrients, 13.","DOI":"10.3390\/nu13092907"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jcf.2020.11.008","article-title":"GOAL-e2 Investigators Long Term Clinical Effectiveness of Ivacaftor in People with the G551D CFTR Mutation","volume":"20","author":"Guimbellot","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of Elexacaftor-Tezacaftor-Ivacaftor on Body Weight and Metabolic Parameters in Adults with Cystic Fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor Treatment of Cystic Fibrosis in Children Aged 12 to <24 Months and with a CFTR Gating Mutation (ARRIVAL): A Phase 3 Single-Arm Study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"eaau7531","DOI":"10.1126\/scitranslmed.aau7531","article-title":"In Utero and Postnatal VX-770 Administration Rescues Multiorgan Disease in a Ferret Model of Cystic Fibrosis","volume":"11","author":"Sun","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/ajcn\/nqy188","article-title":"Type of Infant Formula Increases Early Weight Gain and Impacts Energy Balance: A Randomized Controlled Trial","volume":"108","author":"Mennella","year":"2018","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Stallings, V.A., Tindall, A.M., Mascarenhas, M.R., Maqbool, A., and Schall, J.I. (2020). Improved Residual Fat Malabsorption and Growth in Children with Cystic Fibrosis Treated with a Novel Oral Structured Lipid Supplement: A Randomized Controlled Trial. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0239642"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jcf.2021.09.010","article-title":"CFTR Modulators Increase Risk of Acute Pancreatitis in Pancreatic Insufficient Patients with Cystic Fibrosis","volume":"21","author":"Gould","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"E16","DOI":"10.1002\/ppul.24353","article-title":"Time for a Gut Check: Pancreatic Sufficiency Resulting from CFTR Modulator Use","volume":"54","author":"Megalaa","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.14309\/ajg.0000000000001527","article-title":"Cystic Fibrosis Transmembrane Conductance Regulator Modulator Use Is Associated With Reduced Pancreatitis Hospitalizations in Patients With Cystic Fibrosis","volume":"116","author":"Ramsey","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/MCP.0000000000000819","article-title":"Triple Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in the Real World\u2014Opportunities and Challenges","volume":"27","author":"Barry","year":"2021","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Scotet, V., L\u2019Hostis, C., and F\u00e9rec, C. (2020). The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery. Genes, 11.","DOI":"10.3390\/genes11060589"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/MCP.0000000000000734","article-title":"Editorial: The Changing Landscape of Cystic Fibrosis: New Therapies, Challenges and a Global Pandemic","volume":"26","author":"Barry","year":"2020","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/MCP.0000000000000727","article-title":"Changing Landscape: Psychological Care in the Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulators","volume":"26","author":"Havermans","year":"2020","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/MCP.0000000000000917","article-title":"Nutritional and Metabolic Management for Cystic Fibrosis in a Post-Cystic Fibrosis Transmembrane Conductance Modulator Era","volume":"28","author":"Wilschanski","year":"2022","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s41030-020-00115-8","article-title":"Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012\u20132016 Experience","volume":"6","author":"Higgins","year":"2020","journal-title":"Pulm. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"639475","DOI":"10.3389\/fphar.2021.639475","article-title":"Treatment of Cystic Fibrosis: From Gene- to Cell-Based Therapies","volume":"12","author":"Allan","year":"2021","journal-title":"Front. Pharm."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR Modulator Theratyping: Current Status, Gaps and Future Directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"423","DOI":"10.31925\/farmacia.2019.3.7","article-title":"25(OH) vitamin D deficiency in cystic fibrosis children\u2014A prospective study on prevalence and treatment outcome","volume":"67","author":"Stan","year":"2019","journal-title":"Farmacia"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/1\/162\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T17:57:21Z","timestamp":1760119041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/1\/162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,3]]},"references-count":124,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["pharmaceutics15010162"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15010162","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,3]]}}}